Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical will set February 28, 2026, effectively February 27 due to the weekend, as the record date to determine shareholders eligible to vote at an extraordinary general meeting expected in mid-April. The move follows a tender offer by TAIYO KOSAN that could lead to a management buyout and leave the offeror and remaining non-tendering shareholders as the only owners.
If the tender offer does not acquire all targeted shares, the extraordinary meeting is expected to vote on a share consolidation under Japan’s Companies Act and an amendment to abolish unit-share provisions, enabling a squeeze-out of remaining minority holders. However, if the offer fails to complete or succeeds in acquiring all relevant shares via the tender, the company will not hold the meeting and the record date will effectively lapse.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen7130.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company known for its topical analgesic products and transdermal patches. The company focuses on pain relief and related healthcare solutions, serving both domestic and international markets through prescription and over-the-counter medicines.
Average Trading Volume: 342,533
Technical Sentiment Signal: Buy
Current Market Cap: Yen475B
For an in-depth examination of 4530 stock, go to TipRanks’ Overview page.